网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
分化型甲状腺癌骨转移预测模型的构建
作者:石福民  张宏伟  翟健  梁金屏 
单位:唐山市人民医院 头颈外科, 河北 唐山 063000
关键词:分化型甲状腺癌 骨转移 危险因素 预测模型 
分类号:R736.1
出版年·卷·期(页码):2021·49·第一期(13-17)
摘要:

目的: 研究分化型甲状腺癌骨转移危险因素,并建立预测模型。方法: 选择2014年1月至2019年1月来本院肿瘤科治疗的符合纳排标准的1 000例分化型甲状腺癌患者作为研究对象,根据是否发生骨转移将患者分成骨转移组(n=39)和非骨转移组(n=961),单因素分析两组患者一般资料,并对差异有统计学意义的单因素行非条件Logistic多因素分析,得出甲状腺癌骨转移的独立危险因素,建立并评估其预测价值。结果:两组患者年龄、病灶数、病理分型、颈部淋巴结是否清扫、肿瘤是否甲状腺外浸润及术后首次清甲时间等差异有统计学意义(P<0.05),而性别、手术方式、肿瘤最大直径、颈部淋巴结是否转移及TNM分期等差异无统计学意义(P>0.05)。Logistic回归分析表明,术后清甲时间(≥ 6个月,OR=6.679,95% CI为4.576~9.750)、年龄(18~45岁,OR=0.018,95% CI为0.001~0.507)、颈部淋巴结清扫(OR=3.074,95% CI为2.468~3.829)、肿瘤甲状腺外浸润(OR=2.140,95% CI为1.067~4.292)及多病灶癌(OR=2.296,95% CI为1.136~4.640)等5项指标差异具有统计学意义(P<0.05);Logistic回归模型logit(P)=-6.421+1.899X1-4.037X2+1.123X3+0.761X4+0.831X5,其中X1代表术后清甲时间(≥ 6个月),X2代表年龄(18~45岁),X3代表颈部淋巴结清扫,X4代表肿瘤甲状腺外浸润,X5代表多病灶癌。术后清甲时间(≥ 6个月)、年龄(18~45岁)、颈部淋巴结清扫、肿瘤甲状腺外浸润及多病灶癌的ROC曲线下面积分别为0.869(95% CI为0.831~0.907)、0.631(95% CI为0.564~0.698)、0.801(95% CI为0.750~0.852)、0.708(95% CI为0.645~0.772)及0.816(95% CI为0.768~0.864),均有一定的预测价值。结论: 术后清甲时间、年龄、淋巴结清扫、肿瘤甲状腺外浸润及多病灶癌等是分化型甲状腺癌骨转移的危险因素,该模型有望用于指导预测骨转移,提高患者生存率。

Objective: To explore the construction of predictive model of bone metastasis in differentiated thyroid carcinoma. Methods: 1 000 differentiated thyroid carcinoma patients from January 2014 to January 2019 treated in our hospital were selected as study objectives, according to the occurrence of bone metastasis, the patients were divided into bone metastasis group(n=39) and non-bone metastasis group(n=961).The basic information of patients was compared for single factor analysis, and the significantly different single factors were analyzed by non-conditional logistic regression analysis, the dangerous factors for DTC bone metastasis and the forecast model were established to determine its predictive value. Results: There were significant differences in age, thyroid focus, number of thyroid lesions, pathological classification, neck lymph node dissection, tumor extra thyroid invasion and the time of thefirst thyroid clearance between the two groups (P<0.05). There was no significant difference in gender, mode of operation, maximum diameter of tumor, metastasis of cervical lymph nodes and TNM stage; Logistic regression analysis showed the postoperative nail clearance time (OR=6.679,95%CI 4.576-9.750), age (18-45 years) (OR=0.018,95%CI 0.001-0.507), cervical lymph node dissection (OR=3.074,95% CI 2.468-3.829), tumor extra thyroid infiltration (OR=2.140,95% CI 1.067-4.292) and multifocal carcinoma (OR=2.296,95% CI 1.136-4.640). The ROC curve showed that the AUC of postoperative nail clearance time(≥ 6 months), age (18-45 years old), cervical lymph node dissection, tumor extrathyroid invasion and multiple focal carcinoma were 0.869 (95% CI 0.831-0.907), 0.631 (95% CI 0.564-0.698), 0.801 (95% CI 0.750-0.852), 0.708 (95% CI 0.645-0.772) and 0.816 (95% CI 0.768-0.864), respectively, all of which had a certain prediction value. Conclusion: Postoperative nail clearance time, age, lymph node dissection, extrathyroid infiltration and multiple focal carcinoma are risk factors for bone metastasis of differentiated thyroid carcinoma. The model is expected to guide the prediction of bone metastasis and improve the survival rate of patients with differentiated thyroid cancer.

参考文献:

[1] HAUGEN B R,SAWKA A M,ALEXANDER E K,et al.American Thyroid Association Guidelines on the management of thyroid nodules and differentiated thyroid cancer task force review and recommendation on the proposed rena ming of encapsulated follicular variant papillary thyroid carcinoma without invasion to noninvasive follicular thyroid neoplasm with papillary-like nuclear features[J].Thyroid,2017,27(4):481-483.
[2] 邵礼成,菅洪健,陈广辉,等.中青年分化型甲状腺癌患者术后复发与生存分析[J].南方医科大学学报,2017,37(2):274-277.
[3] MOORE M D,POSTMA E,GRAY K D,et al.Less is more:the impact of multidisciplinary thyroid conference on the treatment of well-differentiated thyroid carcinoma[J].World J Surg,2018,42(2):343-349.
[4] OSORIO M,MOUBAYED S P,SU H,et al.Systematic review of site distribution of bone metastases in differentiated thyroid cancer[J].Head Neck,2017,39(4):812.
[5] 王丹阳,张笃安,徐菁,等.18F-FDG PET/CT在分化型甲状腺癌骨转移131I治疗疗效评估中的价值[J].中华核医学与分子影像杂志,2018,38(6):399-402.
[6] LIM H,DEVESA S S,SOSA J A,et al.Trends in thyroid cancer incidence and mortality in the United States,1974-2013[J].JAMA,2017,317(13):1338-1348.
[7] AHMED N,NIYAZ K,BORAKATI A,et al.Hybrid SPECT/CT imaging in the management of differentiated thyroid carcinoma[J].Asian Pac J Cancer Prev,2018,19(2):303-308.
[8] ALAN S N,TOKLU T,BEYKAN S,et al.Evaluation of the dosimetry approaches in ablation treatment of thyroid cancer[J].J Appl Clin Med Phys,2018,19(4):134-140.
[9] 梁艳芳,温清泉,梁颖莹,等.不同放射剂量放疗对甲状腺癌术后残余癌患者生存期和淋巴细胞亚群的影响[J].中国普通外科杂志,2017,26(11):1485-1488.
[10] GLOMSKI K,NOSé V,FAQUIN W C,et al.Metastatic follicular thyroid carcinoma and the primary thyroid gross exa mination:institutional review of cases from 1990 to 2015[J].Endocr Pathol,2017,28(2):177-185.
[11] 林岩松.有关分化型甲状腺癌核医学相关诊治的指南更新[J].中华核医学与分子影像杂志,2018,38(3):172-177.
[12] ESPOSITO M,GUISE T,KANG Y.The biology of bone metastasis[J].Cold Spring Harb Perspect Med,2017,8(6):a031252.
[13] GERSHMAN B,THOMPSON R H,MOREIRA D M,et al.Radical nephrectomy with or without lymph node dissection for nonmetastatic renal cell carcinoma:a propensity score-based analysis[J].Eur Urol,2017,71(4):560-567.
[14] 朱郧鹤,骆磊,孙鹏,等.131I剂量差异对根治术后中低危甲状腺癌患者清甲成功率及反应效果的影响[J].标记免疫分析与临床,2017,24(5):526-529.
[15] LIU B,QIN H,ZHANG B,et al.Significance of clearing differentiated thyroid carcinoma lymph node by high-frequency color Doppler ultrasonography[J].Oncology Letters,2017,13(1):253-257.
[16] NIXON I J,COCA-PELAZ,KALEVA A I,et al.Metastasis to the thyroid gland:a critical review[J].Ann Surg Oncol,2017,24(6):1533-1539.
[17] 刘文,程若川,苏艳军,等.甲状腺乳头状癌中央区淋巴结转移危险因素研究(附3273例回顾性分析)[J].中国实用外科杂志,2018,38(3):316-321.
[18] 徐倪侦,田文,费阳.40例分化型甲状腺癌术后骨转移时间的影响因素分析[J].解放军医学院学报,2017,38(12):1114-1117,1126.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 458632 位访问者


 ©《现代医学》编辑部
联系电话:025-83272481;83272479
电子邮件: xdyx@pub.seu.edu.cn

苏ICP备09058541